How Can We Help?
You are here:
< Back

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]

On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]

References

  1. ^ "voxilaprevir_msds".
  2. ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
  3. ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
  4. ^ FDA approves Vosevi for Hepatitis C


Categories
Table of Contents